Biosimilar drug product development to commercialization requires risk based approach. The utilization of FMEA based risk assessment for drug product stage wise process validation will be presented with the emphasis on operating parameters criticality assessment, control strategy and continuous verification

FMEA based characterization of biosimilar drug product manufacturing

251st National Meeting (2016)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.